It is the cache of http://www.dovepress.com/comparative-study-of-1prn-ranibizumab-versus-bevacizumab-in-the-clinic-a10454. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clini
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14789

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting



Original Research

(2797) Total Article Views


Authors: Carneiro AM, Mendonça LS, Falcão MS, Fonseca SL, Brandão EM, Falcão-Reis FM

Published Date July 2012 Volume 2012:6 Pages 1149 - 1157
DOI: http://dx.doi.org/10.2147/OPTH.S33017

Angela M Carneiro,1,2 Luis S Mendonça,1 Manuel S Falcão,1,2 Sofia L Fonseca,1 Elisete M Brandão,1 Fernando M Falcão-Reis1,2

1Department of Ophthalmology of Hospital de São João, Porto, Portugal; 2Faculty of Medicine of University of Porto, Porto, Portugal

Purpose: We compared the efficacy of intravitreal ranibizumab and bevacizumab for treating neovascular age-related macular degeneration using an on-demand regimen.
Methods: A total of 186 wet age-related macular degeneration eyes of 186 treatment-naïve patients were compared retrospectively (67 eyes treated with ranibizumab with 91 treated with bevacizumab). At baseline, mean age, best corrected visual acuity, and angiographic lesion types were similar in both groups. Best corrected visual acuity and ocular coherence tomography were evaluated.
Results: Sixty eyes treated with ranibizumab and 85 eyes treated with bevacizumab completed a 12-month evaluation. At 12 months, mean best corrected visual acuity increased by +6.65 letters with ranibizumab treatment and by +5.59 with bevacizumab treatment (P = 0.64). Visual acuity improved by ≥15 letters in 15 eyes treated with ranibizumab and in 21 eyes treated with bevacizumab (P = 0.75). An overall reduction in ocular coherence tomography central thickness occurred for all time points. The mean number of injections per eye was 5.97 with ranibizumab and 5.92 with bevacizumab (P = 0.90).
Conclusion: Intravitreal therapies with ranibizumab or bevacizumab have similar visual and anatomical results. These results confirm those of comparison of Age-Related Macular Degeneration Treatment Trials in as-needed cohorts in clinical practice. Randomized long-term clinical trials are necessary to examine the systemic safety of these treatments.

Keywords: AMD, anti-VEGF therapy, bevacizumab, choroidal neovascularization, ranibizumab, wet AMD

 




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Manuel Falcão


Readers of this article also read: